Treatment with GH is associated with high insulin-like growth factor 1 (IGF-1) levels which may lead to enhanced growth of upper airway lymphoid tissues, including adenotonsillar hypertrophy which may contribute to OSA within first two years of therapy [1, 4]. This evidence concerns the gene GH1 and obstructive sleep apnea syndrome.